Previous Article | Next Article ![]()
Infection and Immunity, January 2006, p. 296-304, Vol. 74, No. 1
0019-9567/06/$08.00+0 doi:10.1128/IAI.74.1.296-304.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Biology, Austin Peay State University, Clarksville, Tennessee 37044,1 Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 731042
Received 23 May 2005/ Returned for modification 5 July 2005/ Accepted 20 October 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Since the elucidation of the B. burgdorferi genome by Fraser and colleagues (23), numerous genes encoding putative outer surface proteins have been identified using computer-based algorithms. The putative surface proteins identified all share an N-terminal signal peptide, which is needed to direct protein export through the B. burgdorferi cytoplasmic membrane (26, 51). Unfortunately, while many putative surface proteins have been described, few have been empirically verified to be surface exposed and expressed during both tick transmission and mammalian infection. However, using the combined genome sequence information in conjunction with the transcriptional profiling studies previously performed in our laboratory (6, 48), we were able to identify a subset of putative Osps that are expressed during tick transmission and mammalian infection.
A majority of the genes encoding putative Osps that were identified in the microarray studies were down-regulated by temperature and mammalian host factors (6, 48). However, at least 10 putative Osps were identified that were up-regulated by these environmental cues and were subsequently selected for further study. Here we show, using a combination of Triton X-114 phase partitioning and cellular localization experiments, that 7 of the 10 candidates were determined to be bona fide Osps that are surface exposed in B. burgdorferi. Consistent with the cellular localization analyses, specific antibodies generated against all seven Osps were bactericidal towards B. burgdorferi. The combined studies have identified seven previously unrecognized Osps from B. burgdorferi that can now be further examined for their role(s) in Lyme disease pathogenesis and for their ability to be used as novel vaccinogens.
| MATERIALS AND METHODS |
|---|
|
|
|---|
as the host strain and tryptone-yeast broth or agar medium supplemented with the appropriate antibiotic. Hydrophilicity analysis and identification of signal peptides. DNA sequences were downloaded from The Institute for Genomic Research website (http://www.tigr.org/tigr-scripts/CMR2/GenomePage3.spl?database = gbb), and hydrophilicity plots were generated using MacVector version 6.5.3 sequence analysis software (Oxford Molecular Ltd., Madison, WI) according to the method of Kyte and Doolittle (37) using a window size of 7. To identify signal peptide export sequences, the first 40 N-terminal amino acids of each protein were subjected to the SignalP 3.0 (5) and LipoP 1.0 (34) algorithms to identify putative signal peptidase I and II processing sites, respectively (see Fig. 1).
|
. All clones generated were verified not to contain PCR errors by DNA sequence analysis. Recombinant glutathione S-transferase (GST) fusion proteins were purified and cleaved free of the GST moiety by use of procedures previously described (2, 3). For histidine-tagged fusion protein purification, transformed E. coli cultures were grown to an optical density at 600 nm (OD600) of 0.8 in tryptone-yeast broth containing 100 µg of ampicillin per ml before being induced with 0.2% L-arabinose (Sigma Chemical Co., St. Louis, MO) overnight. Cells were subsequently harvested by centrifugation at 8,000 x g for 20 min and lysed by sonication in a buffer containing 50 mM Tris-HCl, 50 mM Tris-Base (pH 7.9) (Sigma Chemical Co., St. Louis, MO), 12.5 mM ß-mercaptoethanol before affinity column purification was performed according to the manufacturer's instructions (QIAGEN, Valencia, CA). Purified protein was eluted from the column in 20 mM Tris-HCl, 20 mM Tris-Base (pH 7.9), 100 mM KCl, 12.5 mM ß-mercaptoethanol, 10% glycerol, 200 mM imidazole. All GST and His-tagged recombinant proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and examined by silver staining (45) to verify purity.
|
SDS-PAGE and immunoblot analysis. Whole-cell lysates of B. burgdorferi B31 were boiled for 10 min in final sample buffer (62.5 µM Tris-HCl [pH 6.8], 10% [vol/vol] glycerol, 5% [vol/vol] ß-mercaptoethanol, 5% SDS, 0.001% bromophenol blue) before electrophoresis through a 2.4% stacking and 12.5% separating gel. Gels were transferred electrophoretically to nitrocellulose (Schleicher and Schuell, Keene, N.H.) for immunoblot analysis. Immunoblots were blocked for 45 min in PBS (pH 7.4) containing 0.2% Tween 20 (PBS-T). To analyze specific reactivity of immunized rat sera to whole-cell lysates and the various recombinant proteins, transferred proteins were incubated with a 1:1,000 dilution of the primary rat serum for 45 min followed by three washes with PBS-T. Subsequently, 1:1,000 dilutions of horseradish peroxidase (HRP)-conjugated goat anti-rat antibody or anti-rabbit antibody (Zymed, San Francisco, CA) were incubated with the membranes for 45 min. Membranes were washed for 30 min with PBS before being developed with the chromogenic substrate 4-chloro-1-naphthol. For enhanced chemiluminescence immunoblotting, membranes were initially blocked for 45 min in PBS-T followed by blocking overnight in PBS-T-10% fetal calf serum (Difco Laboratories, Detroit, MI). Membranes were then washed three times in PBS-T for 10 min before being incubated for 45 min with a 1:2,000 dilution of the primary rat antibodies in Blotto HD (2% IGEPAL, 0.2% SDS, 28 mM Tris-HCl, 22 mM Tris-Base, 1.5 mM calcium chloride, and 80 mM sodium chloride). After incubation with primary antibodies, the membranes were washed three times in Blotto HD-0.2% bovine serum albumin and a 1:5,000 dilution of HRP-conjugated goat anti-rat or anti-rabbit antibody in Blotto HD was added and allowed to incubate with the membranes for 45 min. Membranes were then washed three times for 10 min with PBS (pH 7.4) before being developed with the enhanced chemiluminescence plus reagent provided by the manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ).
Triton X-114 phase partitioning.
To examine the amphiphilic characteristics of the candidate Osps, 1 x 109 spirochetes were sonicated on ice in 800 µl PBS four times for 20 s. Two hundred microliters of 10% Triton X-114 (Sigma Chemical Co.) was then added to the sonicated samples before being rocked overnight at 4°C. Following incubation at 4°C, phase-partitioned lysates were centrifuged at 13,000 x g for 15 min at 4°C to remove insoluble cell debris. The resulting supernatant was removed and placed at 37°C to allow for phase separation. The resulting aqueous and detergent-enriched phases were then each washed five times as previously described (7). A total of 10 volumes of ice-cold acetone was then added to both the detergent and aqueous phases followed by centrifugation at 13,000 x g for 15 min to precipitate proteins. Protein pellets were resuspended in PBS (pH 7.4), and equivalent amounts of cell lysates from each phase (
1 x 108 organisms) were subjected to SDS-PAGE before transfer to nitrocellulose for immunoblot analysis as described above.
PK surface localization. To remove adherent serum proteins from spirochetes, 2 x 108 organisms were gently washed three times in 1 ml of PBS (pH 7.4); spirochetes were gently collected between after wash by centrifugation at 4,000 x g for 4 min. Subsequently, the washed spirochetes were resuspended in 1 ml of PBS and split into two equal 500-µl volumes. One aliquot received 200 µg of proteinase K (PK) (Sigma Chemical Co.), while the other aliquot received an equal volume of PBS without PK. Both aliquots were incubated for 1 h at room temperature before 10 µl of phenylmethylsulfonyl fluoride (Sigma Chemical Co.) was added to stop PK activity. Spirochete suspensions were subsequently pelleted by centrifugation at 10,000 x g for 10 min and resuspended in PBS for immunoblot analysis.
Bactericidal assay. Antibodies generated against FlaB, GST, thioredoxin, OspA, Bb0405, Bb0689, BbA66, BbA64, BbA36, BbA69, and BbI42 were used for B. burgdorferi bactericidal assays. B. burgdorferi organisms (4 x 106) were seeded into wells of a 96-well flat-bottom microtiter plate containing either 2 units of normal guinea pig complement alone (Sigma Chemical Co.) or normal guinea pig complement with a 1:10 dilution of the antibody preparations. Plates were sealed and incubated at 34°C for 72 h. Aliquots of each well were examined by dark-field microscopy to quantitate cell survival and percent inhibition (44). All assays were performed in triplicate. Statistical significance was determined using the unpaired, two-tailed Student's t test (15).
Enzyme-linked immunosorbent assay (ELISA). One hundred nanograms of each recombinant protein was diluted in 50 µl of PBS (pH 7.4) prior to plating in triplicate in 96-well Maxisorp Nunc-Immuno plates (Nalge Nunc International, Naperville, Ill.). Samples were allowed to coat overnight at 4°C. For end point titers, serum samples taken from tick-infested baboons 0, 42, 90, 180, and 360 days post tick infestation were initially diluted 1:100 and then serially diluted twofold to a final dilution of 1:25,600. Secondary antibodies were HRP-conjugated sheep anti-human immunoglobulin, isotypes G (gamma chain) and M (mu chain) specific (The Binding Site, San Diego, CA), which were previously demonstrated to react with baboon antibodies (27). Antibody end point titers were determined as the highest dilution for which the mean OD405 was 3 standard deviations above the mean OD405 of the same dilution of serum added to wells coated with blocking reagent alone.
| RESULTS |
|---|
|
|
|---|
To confirm that the expression patterns of these proteins corresponded to the prior transcriptional profiles determined by microarray analyses, we also performed chemiluminescent immunoblot analyses for 6 of the 10 candidate outer surface proteins identified. As shown in Fig. 2, all six proteins analyzed (BbA36, BbA57, BbA64, BbA66, BbI42, and Bb0405) were up-regulated by temperature shift and by cultivation within a mammalian host. These data were consistent with the transcriptional regulation previously observed in microarray analyses (6, 48). As a control and to confirm that spirochetes responded appropriately to temperature shift and mammalian host adaptation, the constitutively expressed FlaB protein was not observed to be differentially expressed by temperature- or by mammalian host-adapted spirochetes. By contrast, OspC was dramatically up-regulated by temperature and in mammalian host-adapted spirochetes whereas OspA was dramatically down-regulated in mammalian host-adapted organisms, as expected (1, 12, 29, 57).
|
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Among the seven new surface proteins identified, six were observed to contain typical signal peptidase II processing and modification sites, indicating that they are anchored to the borrelial surface by their lipid moieties. Currently, only the sec-dependent pathway has been identified in B. burgdorferi for the export of proteins. However, this secretion system still has not been fully characterized and some of the secretion components found in other bacteria either appear to be absent in B. burgdorferi or have not yet been identified (23, 26). It currently is believed that all proteins destined for the borrelial surface contain a typical N-terminal signal peptide and are exported by the sec-dependent pathway. Lipoproteins that are destined for translocation across the inner membrane can be identified based on a well-conserved signal peptidase II cleavage and modification site terminated by a cysteine residue that becomes lipid modified during transport (56). During export, glycerol modification of the terminal cysteine in the mature protein and subsequent lipid modification results in two fatty acids being covalently attached to the glycerol; a third fatty acid is then added directly to the N-terminal cysteine during modification within the periplasm. The three hydrophobic fatty acid moieties then anchor otherwise hydrophilic proteins to hydrophobic membrane bilayers. To identify lipid-modified proteins, phase partitioning using Triton X-114 has been shown to be a useful technique because it can selectively separate molecules on the basis of their amphipathic characteristics (7). This unique property of Triton X-114 was exploited to examine the solubility properties of the native proteins identified. As shown in Fig. 3, all candidate lipoproteins partitioned into the detergent phase as expected. This finding strongly suggests that the otherwise hydrophilic Bb0689, BbA36, BbA64, BbA66, BbA69, and BbI42 proteins are lipid modified. The native form of Bb0405 was found to selectively partition into the detergent phase, which is consistent with this protein containing membrane-spanning domains that traverse the outer membrane.
The PK experiments also indicated that Bb0405, the integral outer membrane protein identified, also is surface exposed. This observation is important, since only one other integral outer membrane protein has been identified thus far in B. burgdorferi. The other integral outer membrane protein, designated p66, that has been characterized has been shown to be an integrin binding protein (10, 17). Based on the observation that p66 binds beta (3)-chain integrins (10), which is thought to help B. burgdorferi bind platelets and megakaryocytes in the mammalian host, it is tempting to speculate that Bb0405 also plays an important role in host-pathogen interactions during infection. Furthermore, the observation that bb0405 is up-regulated by temperature and stays up-regulated during mammalian infection (6, 48) suggests that Bb0405 is important during both tick transmission and the early dissemination stage of Lyme disease. This conjecture could be tested by deleting or mutating the bb0405 gene in a virulent strain of B. burgdorferi and determining whether this alters borrelial transmission or dissemination within the mammalian host. Experiments of this nature are now feasible given recent advances that have made it possible to genetically manipulate at least some virulent strains of B. burgdorferi (20, 21, 30, 40).
Of the seven surface proteins identified in this study, one was recently characterized for its expression by B. burgdorferi in mice and for its ability to protect mice from experimental Lyme disease infection. Consistent with our prior microarray data and the data shown here, these recent studies showed that bbA36 is expressed during mammalian infection for at least 4 months (41) and that antibodies directed against BbA36 could passively protect immunodeficient mice from infection (62). However, when bbA36 was specifically inactivated in a virulent B. burgdorferi strain in a recent study by Norgard and coworkers (54), no differential phenotype was observed for this mutant in either the mouse or tick environment. While the function of BbA36 on the surface of B. burgdorferi is still unknown, the combined studies provide empirical evidence that our strategy for identifying viable second-generation Lyme disease vaccinogens is promising.
A major outcome of these studies is the finding that antibodies generated against all seven of the newly identified surface proteins could kill B. burgdorferi. Therefore, all seven can be considered candidates for further vaccine studies in animals. However, this observation also raises a paradox since B. burgdorferi can persist in infected animals even in the presence of specific antibodies against all seven of these proteins. One possible explanation for this phenomenon is that B. burgdorferi colonizes immune-privileged niches during early infection (24, 50) or localizes to tissues with a low penetration of antibody and/or immune effector cells, which would allow organisms to persist in the presence of a specific and robust immune response (11, 24, 47, 50, 59). Therefore, as long as B. burgdorferi can colonize immune-restricted tissue niches before an immune response develops, they are protected and can chronically persist in the mammalian host. Examining the protective nature of antibodies generated in animals prior to infection will allow us to assess this important issue. Preliminary studies have supported this notion. For example, when immunocompetent C3H/HeJ mice were actively immunized with Bb0689 and BbA36, both antigens were able to protect mice from subsequent challenge with 1 x 105 B. burgdorferi bacteria by syringe inoculation (C. S. Brooks and D. R. Akins, unpublished observations). These studies will be expanded in future experiments to include all seven surface proteins identified using animals infected by tick infestation.
In conclusion, we identified seven B. burgdorferi surface proteins by focusing our efforts on a subset of genes previously identified as up-regulated during transmission and infection by use of microarray analyses (6, 48). Among the candidate surface proteins identified in the microarray analyses, a subset of 10 was found to be up-regulated and putatively located on the surface of B. burgdorferi. PK accessibility experiments verified that 7 of the initial 10 proteins are bona fide outer surface proteins in B. burgdorferi. Given the paucity of outer surface proteins that have been identified in B. burgdorferi over the last decade, the results of this study are an important advance in the field and lay the foundation for future work aimed at defining the roles of these proteins in B. burgdorferi physiology and host-pathogen interactions. Tick-infested baboons were observed to generate specific humoral responses to all seven of the surface proteins during the course of infection. Additionally, baboons maintained circulating antibodies against all seven proteins for at least 1 year postinfection while bactericidal assays revealed that all seven surface proteins are targets for killing B. burgdorferi in vitro. The combined data suggest that these newly identified surface proteins are (i) actively expressed during a natural tick-derived infection, (ii) immunogenic during infection, (iii) exposed targets for bactericidal antibody, and (iv) candidate vaccine molecules for Lyme disease. Furthermore, since these molecules are surface exposed and up-regulated during infection, they are likely integral to the parasitic strategy utilized by B. burgdorferi and may be important virulence determinants. With the recent advances in borrelial mutagenesis techniques, future studies will include selectively targeting these genes and disrupting their function to better understand their role(s) in borrelial virulence and Lyme disease pathogenesis.
| ACKNOWLEDGMENTS |
|---|
We acknowledge the Borrelia sequencing group of Sherwood R. Casjens, John J. Dunn, Benjamin J. Luft, Claire M. Fraser, Wei-Gang Qiu, and Steven E. Schutzer, working under grants from the Lyme Disease Association and National Institutes of Health (AI37256 and AI49003), for access to unpublished sequence information.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Akins, D. R., K. W. Bourell, M. J. Caimano, M. V. Norgard, and J. D. Radolf. 1998. A new animal model for studying Lyme disease spirochetes in a mammalian host-adapted state. J. Clin. Investig. 101:2240-2250.[Medline] |
| 2. | Akins, D. R., S. F. Porcella, T. G. Popova, D. Shevchenko, S. I. Baker, M. Li, M. V. Norgard, and J. D. Radolf. 1995. Evidence for in vivo but not in vitro expression of a Borrelia burgdorferi outer surface protein F (OspF) homolog. Mol. Microbiol. 18:507-520.[CrossRef][Medline] |
| 3. | Akins, D. R., B. K. Purcell, M. Mitra, M. V. Norgard, and J. D. Radolf. 1993. Lipid modification of the 17-kilodalton membrane immunogen of Treponema pallidum determines macrophage activation as well as amphiphilicity. Infect. Immun. 61:1202-1210. |
| 4. | Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:521-525.[Medline] |
| 5. | Bendtsen, J. D., H. Nielsen, G. von Heijne, and S. Brunak. 2004. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340:783-795.[CrossRef][Medline] |
| 6. | Brooks, C. S., P. S. Hefty, S. E. Jolliff, and D. R. Akins. 2003. Global analysis of Borrelia burgdorferi genes regulated by mammalian host-specific signals. Infect. Immun. 71:3371-3383. |
| 7. | Brusca, J. S., and J. D. Radolf. 1994. Isolation of integral membrane proteins by phase partitioning with Triton X-114. Methods Enzymol. 228:182-193.[Medline] |
| 8. | Centers for Disease Control. 2004. Lyme disease-United States, 2001-2002. Morbid. Mortal. Wkly. Rep. 53:365-369. |
| 9. | Champion, C. I., D. R. Blanco, J. T. Skare, D. A. Haake, M. Giladi, D. Foley, J. N. Miller, and M. A. Lovett. 1994. A 9.0-kilobase-pair circular plasmid of Borrelia burgdorferi encodes an exported protein: evidence for expression only during infection. Infect. Immun. 62:2653-2661. |
| 10. | Coburn, J., W. Chege, L. Magoun, S. C. Bodary, and J. M. Leong. 1999. Characterization of a candidate Borrelia burgdorferi beta(3)-chain integrin ligand identified using a phage display library. Mol. Microbiol. 34:926-940.[CrossRef][Medline] |
| 11. | Coburn, J., M. Medrano, and C. Cugini. 2002. Borrelia burgdorferi and its tropisms for adhesion molecules in the joint. Curr. Opin. Rheumatol. 14:394-398.[CrossRef][Medline] |
| 12. | Coleman, J. L., J. A. Gebbia, J. Piesman, J. L. Degen, T. H. Bugge, and J. L. Benach. 1997. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 89:1111-1119.[CrossRef][Medline] |
| 13. | Connolly, S. E., and J. L. Benach. 2005. The versatile roles of antibodies in Borrelia infections. Nat. Rev. Microbiol. 3:411-420.[CrossRef][Medline] |
| 14. | Cox, D. L., D. R. Akins, K. W. Bourell, P. Lahdenne, M. V. Norgard, and J. D. Radolf. 1996. Limited surface exposure of Borrelia burgdorferi outer surface lipoproteins. Proc. Natl. Acad. Sci. USA 93:7973-7978. |
| 15. | Daniel, W. W. 1999. Biostatistics: a foundation for analysis in the health sciences. John Wiley and Sons, Inc., New York, N.Y. |
| 16. | Das, S., S. W. Barthold, S. S. Giles, R. R. Montgomery, S. R. Telford, and E. Fikrig. 1997. Temporal pattern of Borrelia burgdorferi p21 expression in ticks and mammalian host. J. Clin. Investig. 99:987-995.[Medline] |
| 17. | Defoe, G., and J. Coburn. 2001. Delineation of Borrelia burgdorferi p66 sequences required for integrin IIbß3 recognition. Infect. Immun. 69:3455-3459. |
| 18. | de Silva, A. M., and E. Fikrig. 1997. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J. Clin. Investig. 99:377-379.[Medline] |
| 19. | de Silva, A. M., E. Fikrig, E. Hodzie, F. S. Kantor, S. R. Telford III, and S. W. Barthold. 1998. Immune evasion by tickborne and host-adapted Borrelia burgdorferi. J. Infect. Dis. 177:395-400.[Medline] |
| 20. | Eggers, C. H., M. J. Caimano, M. L. Clawson, W. G. Miller, D. S. Samuels, and J. D. Radolf. 2002. Identification of loci critical for replication and compatibility of a Borrelia burgdorferi cp32 plasmid and use of a cp32-based shuttle vector for the expression of fluorescent reporters in the Lyme disease spirochaete. Mol. Microbiol. 43:281-295.[CrossRef][Medline] |
| 21. | Elias, A. F., P. E. Stewart, D. Grimm, M. J. Caimano, C. H. Eggers, K. Tilly, J. L. Bono, D. R. Akins, J. D. Radolf, T. G. Schwan, and P. Rosa. 2002. Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background. Infect. Immun. 70:2139-2150. |
| 22. | Fikrig, E., S. W. Barthold, W. Sun, W. Feng, S. R. Telford, and R. A. Flavell. 1997. Borrelia burgdorferi p35 and p37 proteins, expressed in vivo, elicit protective immunity. Immunity 6:531-539.[CrossRef][Medline] |
| 23. | Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lathigra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, M. Gwinn, B. Dougherty, J.-F. Tomb, R. D. Fleischmann, D. Richardson, J. Peterson, A. R. Kerlavage, J. Quackenbush, S. Salzberg, M. Hanson, R. van Vugt, N. Palmer, M. D. Adams, J. Gocayne, J. Weidman, T. Utterback, L. Watthey, L. McDonald, P. Artiach, C. Bowman, S. Garland, C. Fujii, M. D. Cotton, K. Horst, K. Roberts, B. Hatch, H. O. Smith, and J. C. Venter. 1997. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390:580-586.[CrossRef][Medline] |
| 24. | Georgilis, K., M. Peacocke, and M. S. Klempner. 1992. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J. Infect. Dis. 166:440-444.[Medline] |
| 25. | Grimm, D., K. Tilly, R. Byram, P. E. Stewart, J. G. Krum, D. M. Bueschel, T. G. Schwan, P. F. Policastro, A. F. Elias, and P. A. Rosa. 2004. Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proc. Natl. Acad. Sci. USA 101:3142-3147. |
| 26. | Haake, D. A. 2000. Spirochaetal lipoproteins and pathogenesis. Microbiology 146:1491-1504. |
| 27. | Hefty, P. S., C. S. Brooks, A. M. Jett, G. L. White, S. K. Wikel, R. C. Kennedy, and D. R. Akins. 2002. OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human Lyme disease patients. J. Clin. Microbiol. 40:4256-4265. |
| 28. | Hefty, P. S., S. E. Jolliff, M. J. Caimano, S. K. Wikel, and D. R. Akins. 2002. Changes in temporal and spatial patterns of outer surface lipoprotein expression generate population heterogeneity and antigenic diversity in the Lyme disease spirochete, Borrelia burgdorferi. Infect. Immun. 70:3468-3478. |
| 29. | Hefty, P. S., S. E. Jolliff, M. J. Caimano, S. K. Wikel, J. D. Radolf, and D. R. Akins. 2001. Regulation of OspE-related, OspF-related, and Elp lipoproteins of Borrelia burgdorferi strain 297 by mammalian host-specific signals. Infect. Immun. 69:3618-3627. |
| 30. | Hubner, A., X. Yang, D. M. Nolen, T. G. Popova, F. C. Cabello, and M. V. Norgard. 2001. Expression of Borrelia burgdorferi OspC and DbpA is controlled by a RpoN-RpoS regulatory pathway. Proc. Natl. Acad. Sci. USA 98:12724-12729. |
| 31. | Johnson, R. C., C. Kodner, and M. Russell. 1986. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect. Immun. 54:897-898. |
| 32. | Johnson, R. C., C. Kodner, and M. Russell. 1986. Passive immunization of hamsters against experimental infection with the Lyme disease spirochete. Infect. Immun. 53:713-714. |
| 33. | Johnson, R. C., C. L. Kodner, and M. E. Russell. 1986. Vaccination of hamsters against experimental infection with Borrelia burgdorferi. Zentralbl. Bakteriol. Mikrobiol. Hyg. 263:45-48. |
| 34. | Juncker, A. S., H. Willenbrock, G. von Heijne, S. Brunak, H. Nielsen, and A. Krogh. 2003. Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci. 12:1652-1662. |
| 35. | Kochi, S. K., and R. C. Johnson. 1988. Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect. Immun. 56:314-321. |
| 36. | Kochi, S. K., R. C. Johnson, and A. P. Dalmasso. 1991. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex. J. Immunol. 146:3964-3970.[Abstract] |
| 37. | Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.[CrossRef][Medline] |
| 38. | Lahdenne, P., S. F. Porcella, K. E. Hagman, D. R. Akins, T. G. Popova, D. L. Cox, J. D. Radolf, and M. V. Norgard. 1997. Molecular characterization of a 6.6-kilodalton Borrelia burgdorferi outer membrane-associated lipoprotein (lp6.6) which appears to be downregulated during mammalian infection. Infect. Immun. 65:412-421.[Abstract] |
| 39. | Lane, R. S., J. Piesman, and W. Burgdorfer. 1991. Lyme borreliosis: relation of its causative agent to its vectors and hosts in North America and Europe. Annu. Rev. Entomol. 36:587-609.[CrossRef][Medline] |
| 40. | Lawrenz, M. B., H. Kawabata, J. E. Purser, and S. J. Norris. 2002. Decreased electroporation efficiency in Borrelia burgdorferi containing linear plasmids lp25 and lp56: impact on transformation of infectious B. burgdorferi. Infect. Immun. 70:4798-4804. |
| 41. | Lerder, S., C. Brenner, T. Stehle, L. Gern, R. Wallich, and M. M. Simon. 2005. Quantitative analysis of Borrelia burgdorferi gene expression in naturally (tick) infected mouse strains. Med. Microbiol. Immunol. 194:81-90.[CrossRef][Medline] |
| 42. | Liang, F. T., F. K. Nelson, and E. Fikrig. 2002. DNA microarray assessment of putative Borrelia burgdorferi lipoprotein genes. Infect. Immun. 70:3300-3303. |
| 43. | Liang, F. T., F. K. Nelson, and E. Fikrig. 2002. Molecular adaptation of Borrelia burgdorferi in the murine host. J. Exp. Med. 196:275-280. |
| 44. | Ma, J., and R. T. Coughlin. 1993. A simple, colorimetric microtiter assay for borreliacidal activity of antisera. J. Microbiol. Methods 145:145-153. |
| 45. | Morrissey, J. H. 1981. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal. Biochem. 117:307-310.[CrossRef][Medline] |
| 46. | Narasimhan, S., M. J. Caimano, F. T. Liang, F. Santiago, M. Laskowski, M. T. Philipp, A. R. Pachner, J. D. Radolf, and E. Fikrig. 2003. Borrelia burgdorferi transcriptome in the central nervous system of non-human primates. Proc. Natl. Acad. Sci. USA 100:15953-15958. |
| 47. | Nocton, J. J. and A. C. Steere. 1995. Lyme disease. Adv. Intern. Med. 40:69-117.[Medline] |
| 48. | Ojaimi, C., C. Brooks, S. Casjens, P. Rosa, A. Elias, A. Barbour, A. Jasinskas, J. Benach, L. Katona, J. Radolf, M. Caimano, J. Skare, K. Swingle, D. Akins, and I. Schwartz. 2003. Profiling of temperature-induced changes in Borrelia burgdorferi gene expression by using whole genome arrays. Infect. Immun. 71:1689-1705. |
| 49. | Orloski, K. A., E. B. Hayes, G. L. Campbell, and D. T. Dennis. 2000. Surveillance for Lyme diseaseUnited States, 1992-1998. MMWR CDC Surveill. Summ. 49:1-9.[Medline] |
| 50. | Pachner, A. R., J. Basta, E. Delaney, and D. Hulinska. 1995. Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am. J. Trop. Med. Hyg. 52:128-133. |
| 51. | Pugsley, A. P. 1993. The complete general secretory pathway in gram-negative bacteria. Microbiol. Rev. 57:50-108. |
| 52. | Radolf, J. D., K. W. Bourell, D. R. Akins, J. S. Brusca, and M. V. Norgard. 1994. Analysis of Borrelia burgdorferi membrane architecture by freeze-fracture electron microscopy. J. Bacteriol. 176:21-31. |
| 53. | Ramamoorthy, R., L. Povinelli, and M. T. Philipp. 1996. Molecular characterization, genomic arrangement, and expression of bmpD, a new member of the bmp class of genes encoding membrane proteins of Borrelia burgdorferi. Infect. Immun. 64:1259-1264.[Abstract] |
| 54. | Revel, A. T., J. S. Blevins, C. Almazan, L. Neil, K. M. Kocan, J. de la Fuente, K. E. Hagman, and M. V. Norgard. 2005. bptA (bbe16) is essential for the persistence of the Lyme disease spirochete, Borrelia burgdorferi, in its natural tick vector. Proc. Natl. Acad. Sci. USA 102:6972-6977. |
| 55. | Sadziene, A., P. A. Thompson, and A. G. Barbour. 1993. In vitro inhibition of Borrelia burgdorferi by antibodies. J. Infect. Dis. 167:165-172.[Medline] |
| 56. | Sankaran, K., S. D. Gupta, and H. C. Wu. 1995. Modification of bacterial lipoproteins. Methods Enzymol. 250:683-697.[Medline] |
| 57. | Schwan, T. G., J. Piesman, W. T. Golde, M. C. Dolan, and P. A. Rosa. 1995. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl. Acad. Sci. USA 92:2909-2913. |
| 58. | Sigal, L. H. 1997. Lyme disease: a review of aspects of its immunology and immunopathogenesis. Annu. Rev. Immunol. 15:63-92.[CrossRef][Medline] |
| 59. | Steere, A. C. 1989. Lyme disease. N. Engl. J. Med. 321:586-597.[Abstract] |
| 60. | Steere, A. C. 1994. Lyme disease: a growing threat to urban populations. Proc. Natl. Acad. Sci. USA 91:2378-2383. |
| 61. | Steere, A. C. 1995. Borrelia burgdorferi (Lyme disease, Lyme borreliosis), p. 2143-2155. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y. |
| 62. | Wallich, R., O. Jahraus, T. Stehle, T. T. Tran, C. Brenner, H. Hofmann, L. Gern, and M. M. Simon. 2003. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease. Eur. J. Immunol. 33:708-719.[CrossRef][Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||